Somatic Genome Alterations in Human Lung Cancers

[1]  L. Rabeneck,et al.  Follow-up of long-term young breast cancer survivors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  David M. Thomas,et al.  FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. , 2012, Cancer discovery.

[3]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[4]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[5]  Herbert Waldmann,et al.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.

[6]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[7]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[8]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[9]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[10]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[11]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[12]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[13]  Roman K. Thomas,et al.  Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants , 2012, Clinical Cancer Research.

[14]  Wendy Winckler,et al.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.

[15]  Kazuko Sakai,et al.  Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[16]  M. Sporn,et al.  NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.

[17]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[18]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[19]  B. Bernstein,et al.  Genetic Events That Shape the Cancer Epigenome , 2012, Science.

[20]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[21]  Kevin Struhl,et al.  SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation , 2012, Nature.

[22]  Paul K. Brindle,et al.  Is histone acetylation the most important physiological function for CBP and p300? , 2012, Aging.

[23]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Seungbok Lee,et al.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.

[25]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[26]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[27]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[28]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[29]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[30]  M. Venkataramanan.  Biotech entrepreneurs swoon over proposed fundraising changes , 2012, Nature Medicine.

[31]  S. Bates.  On Drug Development, Chance, and the Prepared Mind , 2012, Clinical Cancer Research.

[32]  H. Balslev,et al.  Testing the Water–Energy Theory on American Palms (Arecaceae) Using Geographically Weighted Regression , 2011, PloS one.

[33]  Roman K. Thomas,et al.  A crucial requirement for Hedgehog signaling in small cell lung cancer , 2011, Nature Medicine.

[34]  J. Fostel,et al.  Targeted Deletion of Nrf2 Reduces Urethane-Induced Lung Tumor Development in Mice , 2011, PloS one.

[35]  David Haussler,et al.  Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma , 2011, Proceedings of the National Academy of Sciences.

[36]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[37]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[38]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[39]  M. Ferrari,et al.  What does physics have to do with cancer? , 2011, Nature Reviews Cancer.

[40]  T. Shibata,et al.  NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. , 2011, Neoplasia.

[41]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[42]  Wen Tan,et al.  A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese , 2011, Nature Genetics.

[43]  J. Baker,et al.  Transcription and Expression of Plasmodium falciparum Histidine-Rich Proteins in Different Stages and Strains: Implications for Rapid Diagnostic Tests , 2011, PloS one.

[44]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[45]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[46]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[47]  M. Meyerson,et al.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.

[48]  J. Baselga,et al.  The era of cancer discovery. , 2011, Cancer discovery.

[49]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[50]  F. Askin,et al.  KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma , 2011, Journal of Human Genetics.

[51]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[52]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[53]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[54]  Yusuke Nakamura,et al.  A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population. , 2010, Human molecular genetics.

[55]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[56]  H. Greulich,et al.  The genomics of lung adenocarcinoma: opportunities for targeted therapies. , 2010, Genes & cancer.

[57]  M. Foiani,et al.  A lethal combination for cancer cells: synthetic lethality screenings for drug discovery. , 2010, European journal of cancer.

[58]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[59]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[60]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[61]  S. Biswal,et al.  Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. , 2010, Antioxidants & redox signaling.

[62]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[63]  Christopher R. Cabanski,et al.  Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types , 2010, Clinical Cancer Research.

[64]  Yusuke Nakamura,et al.  Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations , 2010, Nature Genetics.

[65]  David P. Davis,et al.  Diverse somatic mutation patterns and pathway alterations in human cancers. , 2010, Nature.

[66]  Jih-Hsiang Lee,et al.  Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors , 2010, Proceedings of the National Academy of Sciences.

[67]  Calum MacAulay,et al.  Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma , 2010, PLoS medicine.

[68]  A. Gemma,et al.  F1000 highlights , 2010 .

[69]  Stephen G Swisher,et al.  Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features , 2010, Clinical Cancer Research.

[70]  Olivia Fletcher,et al.  Architecture of inherited susceptibility to common cancer , 2010, Nature Reviews Cancer.

[71]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[72]  N. Gooderham,et al.  Abstract 6: A triple-helix forming oligonucleotide targeting a genomic locus is capable of sequence specific mutagenesis in human lymphoblastoid TK6 cells , 2010 .

[73]  Marshall W. Anderson,et al.  A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. , 2010, Cancer research.

[74]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[75]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[76]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[77]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[78]  O. Leavy.  Immunology: Inflammatory transformation , 2009, Nature Reviews Cancer.

[79]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[80]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[81]  Ying Wang,et al.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. , 2009, American journal of human genetics.

[82]  M. Meyerson,et al.  Amplification of chromosomal segment 4q12 in non-small cell lung cancer , 2009, Cancer biology & therapy.

[83]  A. Regev,et al.  SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas , 2009, Nature Genetics.

[84]  W. Travis.  Lung tumours with neuroendocrine differentiation. , 2009, European journal of cancer.

[85]  R. Shaw.  Tumor Suppression by LKB1: SIK-ness Prevents Metastasis , 2009, Science Signaling.

[86]  Scott H. Randell,et al.  Basal cells as stem cells of the mouse trachea and human airway epithelium , 2009, Proceedings of the National Academy of Sciences.

[87]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[88]  D. Melton,et al.  Notch signaling promotes airway mucous metaplasia and inhibits alveolar development , 2009, Development.

[89]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[90]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[91]  M. Murawska,et al.  PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients , 2009, Cancer biology & therapy.

[92]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[93]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[94]  S. Hirohashi,et al.  Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. , 2008, Gastroenterology.

[95]  Marshall W. Anderson,et al.  Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. , 2008, Journal of the National Cancer Institute.

[96]  Tsutomu Ohta,et al.  Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.

[97]  J. Sage,et al.  Cellular mechanisms of tumour suppression by the retinoblastoma gene , 2008, Nature Reviews Cancer.

[98]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[99]  Michael Grunstein,et al.  Adenovirus Small e1a Alters Global Patterns of Histone Modification , 2008, Science.

[100]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[101]  M. Day,et al.  The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis , 2008, Oncogene.

[102]  Li Ding,et al.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.

[103]  I Petersen,et al.  Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.

[104]  D. Metzger,et al.  Targeted knockout of BRG1 potentiates lung cancer development. , 2008, Cancer research.

[105]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[106]  Jun Yokota,et al.  Frequent BRG1/SMARCA4–inactivating mutations in human lung cancer cell lines , 2008, Human mutation.

[107]  G A Colditz,et al.  Comparison of aspects of smoking among the four histological types of lung cancer , 2008, Tobacco Control.

[108]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[109]  S. Hirohashi,et al.  Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. , 2008, Cancer research.

[110]  M. Levin.  JAPAN: REVOLUTION ON THE STREETS , 2008 .

[111]  M. Meyerson,et al.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.

[112]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[113]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[114]  J. Kurie,et al.  A genetic mouse model for metastatic lung cancer with gender differences in survival , 2007, Oncogene.

[115]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[116]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[117]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[118]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[119]  M. Meyerson,et al.  The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272 , 2007, Oncogene.

[120]  Y. Yatabe,et al.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.

[121]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[122]  K. Hahm,et al.  Attenuation of dextran sulfate sodium-pomoted mouse colon carcinogenesis by pharmacologic and genetic inhibition of COX-2 , 2007 .

[123]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[124]  Stefano Monti,et al.  Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  S. Biswal,et al.  Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. , 2006, Archives of biochemistry and biophysics.

[126]  Y. Lim,et al.  Protein kinase Calpha can undergo membrane localization via an alternative phosphatidylinositol 4,5-bisphosphate-dependent pathway. , 2006, Archives of biochemistry and biophysics.

[127]  J. Herman,et al.  Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer , 2006, PLoS medicine.

[128]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[129]  M. Meyerson,et al.  Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. , 2006, Cancer research.

[130]  W. Travis,et al.  Pulmonary neuroendocrine tumors: What (little) do we know? , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[131]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[132]  C. Moon,et al.  NMDA receptor type 2A at 16p13 is epigenetically inactivated in human colorectal carcinoma , 2006 .

[133]  S. Miyamoto,et al.  HB-EGF involved in peritoneal implantation of ovarian cancer , 2006 .

[134]  S. Kohno,et al.  Methylation status of BCRP detected by methylation-specific PCR is inversely correlated with its expression and drug resistance in vitro and in patients with cancers , 2006 .

[135]  Takahiro Shibata,et al.  Oxidative and Electrophilic Stresses Activate Nrf2 through Inhibition of Ubiquitination Activity of Keap1 , 2006, Molecular and Cellular Biology.

[136]  M. Molyneux,et al.  Maternal–Fetal Microtransfusions and HIV-1 Mother-to-Child Transmission in Malawi , 2005, PLoS medicine.

[137]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[138]  L. Chin,et al.  High-resolution genomic profiles of human lung cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[139]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[140]  John D. Minna,et al.  Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.

[141]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[142]  Matthew Meyerson,et al.  Somatic alterations in the human cancer genome. , 2004, Cancer cell.

[143]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[144]  David Sidransky,et al.  Genetic and Epigenetic screening for gene alterations of the chromatin‐remodeling factor, SMARCA4/BRG1, in lung tumors , 2004, Genes, chromosomes & cancer.

[145]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[146]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[147]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[148]  G. V. Vande Woude,et al.  Met decoys: will cancer take the bait? , 2004, Cancer cell.

[149]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[150]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[151]  Rameen Beroukhim,et al.  Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. , 2004, Nucleic acids research.

[152]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[153]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[154]  J. Pepper,et al.  A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. , 2004, The New England journal of medicine.

[155]  K. Itoh,et al.  Transcription Factor Nrf2 Regulates Inflammation by Mediating the Effect of 15-Deoxy-Δ12,14-Prostaglandin J2 , 2004, Molecular and Cellular Biology.

[156]  M. J. Richards,et al.  Disturbed Cholesterol Homeostasis in a Peroxisome-Deficient PEX2 Knockout Mouse Model , 2004, Molecular and Cellular Biology.

[157]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[158]  David A Largaespada,et al.  A bad rap: Rap1 signaling and oncogenesis. , 2003, Cancer cell.

[159]  W. Travis,et al.  The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. , 2003, Human pathology.

[160]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[161]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[162]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[163]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[164]  M. Olivier,et al.  TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. , 2001, Mutagenesis.

[165]  H. Clevers,et al.  APC, Signal transduction and genetic instability in colorectal cancer , 2001, Nature Reviews Cancer.

[166]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[167]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[168]  E. Birney,et al.  Cancer and genomics , 2001, Nature.

[169]  E. Kandel,et al.  Neural Science A Century of Progress and the Mysteries that Remain , 2000, Cell.

[170]  I. Wistuba,et al.  Genetic changes in the spectrum of neuroendocrine lung tumors , 1999, Cancer.

[171]  R. Brezinschek,et al.  Mutation analysis of the PTEN/MMAC1 gene in lung cancer , 1998, Oncogene.

[172]  S. Steinberg,et al.  Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. , 1995, Journal of the National Cancer Institute.

[173]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[174]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[175]  M. Wigler,et al.  The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins , 1990, Cell.

[176]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[177]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[178]  J. Minna,et al.  Amplification and expression of the c-myc oncogene in human lung cancer cell lines , 1983, Nature.

[179]  P. Seeburg,et al.  Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations , 1983, Nature.

[180]  A. Feinberg,et al.  Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. , 1983, Science.

[181]  M. Wigler,et al.  Three human transforming genes are related to the viral ras oncogenes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[182]  R. Weinberg,et al.  Human c-Ki-ras2 proto-oncogene on chromosome 12. , 1983, Science.

[183]  R. Weinberg,et al.  Characterization of a human colon/lung carcinoma oncogene , 1983, Nature.

[184]  J. Minna,et al.  Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). , 1982, Science.

[185]  S. Wacholder,et al.  Success of HPV vaccination is now a matter of coverage. , 2012, The Lancet. Oncology.

[186]  Asher Mullard.  Straight talk with...Phil Willis , 2011, Nature Medicine.

[187]  H. Kuerer.  Rational individualised selection of adjuvant therapy for ductal carcinoma in situ. , 2011, The Lancet. Oncology.

[188]  Ping Yang,et al.  GPC5 gene and its related pathways in lung cancer. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[189]  Ruud H. Brakenhoff,et al.  The molecular biology of head and neck cancer , 2011, Nature Reviews Cancer.

[190]  P. Carmeliet,et al.  Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. , 2010, Genes & cancer.

[191]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[192]  S. Mccarroll.  Copy-number analysis goes more than skin deep , 2008, Nature Genetics.

[193]  Sampsa Hautaniemi,et al.  Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. , 2008, Cancer research.

[194]  Genevive Bjorn.  Q &A: Marc Hodosh , 2008, Nature Medicine.

[195]  G. Robertson,et al.  Is B-Raf a good therapeutic target for melanoma and other malignancies? , 2008, Cancer research.

[196]  Gemma K. Alderton.  When DNA damage prevents cancer , 2007, Nature Reviews Cancer.

[197]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[198]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[199]  M. Shichiri,et al.  Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. , 2002, Cancer research.

[200]  C. Fletcher,et al.  Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. , 1995, Cancer research.

[201]  Cooper Cs.  The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor. , 1992, Oncogene.

[202]  J. Minna,et al.  Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer , 1987, Nature.